All In Biotech

Drug Trial Radar · NCT02546661

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in Patients With Muscle Invasive Bladder Cancer (MIBC) Who Have Progressed on Prior Treatment (BISCAY).

Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 117 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

117

Actual

Start

Dec 28, 2016

Primary completion

Mar 18, 2020

Study completion Nov 30, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Sep 11, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, multi-drug, biomarker-directed, multi-centre, multi-arm, Phase 1b study in patients with muscle invasive bladder cancer (MIBC) (urothelial) who have progressed on prior treatment. This study is modular in design, allowing evaluation of the safety, tolerability, pharmacokinetics and anti-tumour activity of multiple agents as monotherapy and as combinations of different novel anti-cancer agents. The study will consist of a number of study modules (sub-studies), each evaluating the safety and tolerability of a specific agent or combination.

Conditions

  • Muscle Invasive Bladder Cancer

Interventions

  • AZD4547Drug

    AZD4547 Monotherapy vs. MEDI4736 (durvalumab) + AZD4547 1:1 Randomization.

  • MEDI4736Drug

    MEDI4736

  • OlaparibDrug

    MEDI4736 (durvalumab) + Olaparib

  • AZD1775Drug

    MEDI4736 (durvalumab) + AZD1775

  • VistusertibDrug

    MEDI4736 (durvalumab) + Vistusertib

  • AZD9150Drug

    MEDI4736 (durvalumab) + AZD9150

  • SelumetinibDrug

    MEDI4736 (durvalumab) + Selumetinib

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Module A: The frequency and nature of adverse events related to AZD4547 monotherapy.Time frame: Adverse events will be assessed at each clinic visit, and at study discontinuation and 90 days after the end of treatment. Clinic visits are generally scheduled weekly.
  2. Module A: The frequency and nature of adverse events related to the combination of intravenous MEDI4736 (durvalumab) and oral AZD4547.Time frame: Adverse events will be assessed at each clinic visit, and at study discontinuation and 90 days after the end of treatment. Clinic visits are generally scheduled weekly.
  3. Module B: The frequency and nature of adverse events related to the combination of intravenous MEDI4736 (durvalumab) and oral olaparib.Time frame: Adverse events will be assessed at each clinic visit, and at study discontinuation and 90 days after the end of treatment. Clinic visits are generally scheduled weekly.
  4. Module C: The frequency and nature of adverse events related to intravenous MEDI4736 (durvalumab) when given in combination with oral AZD1775.Time frame: Adverse events will be assessed at each clinic visit, and at study discontinuation and 90 days after the end of treatment. Clinic visits are generally scheduled weekly.
  5. Module D: The frequency and nature of adverse events related to intravenous MEDI4736 (durvalumab) monotherapy.Time frame: Adverse events will be assessed at each clinic visit, and at study discontinuation and 90 days after the end of treatment. Clinic visits are generally scheduled weekly.
  6. Module E: The frequency and nature of adverse events related to intravenous MEDI4736 (durvalumab) when given in combination with oral vistusertib.Time frame: Adverse events will be assessed at each clinic visit, and at study discontinuation and 90 days after the end of treatment. Clinic visits are generally scheduled weekly.
  7. Module F: The frequency and nature of adverse events related to the combination of intravenous MEDI4736 (durvalumab) and intravenous AZD9150.Time frame: Adverse events will be assessed at each clinic visit, and at study discontinuation and 90 days after the end of treatment. Clinic visits are generally scheduled weekly.
  8. Module G: The frequency and nature of adverse events related to intravenous MEDI4736 (durvalumab) when given in combination with oral selumetinib.Time frame: Adverse events will be assessed at each clinic visit, and at study discontinuation and 90 days after the end of treatment. Clinic visits are generally scheduled weekly.
  9. All Modules: Change from baseline in clinical chemistry parameters.Time frame: Days 1, 8, 15, and 22 of Cycle 1, Days 1, 15, and 22 of Cycles 2 and 3 and every 4 weeks thereafter, and at discontinuation.
  10. All Modules: Change from baseline in haematology parameters.Time frame: Days 1, 8, 15, and 22 of Cycle 1, Days 1, 15, and 22 of Cycles 2 and 3 and every 4 weeks thereafter, and at discontinuation.
  11. All Modules: Change from baseline in urinalysis results.Time frame: Days 1, 8, 15, and 22 of Cycle 1, Days 1, 15, and 22 of Cycles 2 and 3 and every 4 weeks thereafter, and at discontinuation.
  12. All Modules: Change from baseline in vital signs.Time frame: Day 1 of Cycles 1, 2, 3, and 4 and every 4 weeks therafter, and at discontinuation.
  13. All Modules: Change from baseline in physical examination findings.Time frame: Day 1 of Cycles 1, 2, 3, and 4 and every 4 weeks therafter, and at discontinuation.
  14. All Modules: Change from baseline in ECG findings.Time frame: ECGs will be collected at screening, Day 1, Cycle 1and then Day 1 of each cycle from Cycle 2 onwards.
  15. All Modules: Change from baseline in ejection fraction determined by assessing ECHO/MUGA scans.Time frame: Ejection fraction will be measured at screening, on Day 1, Cycle 1, and every 12 weeks thereafter (relative to the first dose of study drug) up to Cycle 7, and then every 16 weeks thereafter.
  16. All Modules: Change from baseline in coagulation parametersTime frame: Coagulation parameters will be measured at screening, on Day 1, Cycle 1, and every 12 weeks thereafter (relative to the first dose of study drug) up to Cycle 7, and then every 16 weeks thereafter.
  17. All Modules: Change from baseline in lipid profileTime frame: Lipid profile will be measured at screening, on Day 1, Cycle 1, and every 12 weeks thereafter (relative to the first dose of study drug) up to Cycle 7, and then every 16 weeks thereafter.

Locations

27 sites in 5 countries. Site status is shown where the registry gives one.

  • Research Site

    Los Angeles, California

  • Research Site

    New Haven, Connecticut

  • Research Site

    Fort Myers, Florida

  • Research Site

    New York, New York

  • Research Site

    New York, New York

  • Research Site

    New York, New York

  • Research Site

    Cleveland, Ohio

  • Research Site

    Nashville, Tennessee

  • Research Site

    Edmonton, Alberta, Canada

  • Research Site

    Vancouver, British Columbia, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Bordeaux, France

  • Research Site

    Caen, France

  • Research Site

    Lyon, France

  • Research Site

    Marseille, France

  • Research Site

    Saint-Herblain, France

  • Research Site

    Toulouse, France

  • Research Site

    Badalona, Spain

  • Research Site

    Barcelona, Spain

  • Research Site

    Barcelona, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Glasgow, United Kingdom

  • Research Site

    London, United Kingdom

  • Research Site

    London, United Kingdom

  • Research Site

    Manchester, United Kingdom

  • Research Site

    Southampton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.